Short Interest in Evotec SE (NASDAQ:EVO) Expands By 2,060.0%

Evotec SE (NASDAQ:EVOGet Free Report) was the recipient of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 54,000 shares, an increase of 2,060.0% from the January 15th total of 2,500 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 65,100 shares, the short-interest ratio is presently 0.8 days.

Analysts Set New Price Targets

Separately, Royal Bank of Canada upgraded Evotec from a “sector perform” rating to an “outperform” rating in a research report on Thursday, January 18th.

Read Our Latest Research Report on Evotec

Evotec Stock Performance

EVO stock opened at $7.62 on Monday. Evotec has a twelve month low of $7.11 and a twelve month high of $13.49. The stock has a fifty day simple moving average of $9.51.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evotec stock. Quadrant Capital Group LLC bought a new stake in shares of Evotec SE (NASDAQ:EVOFree Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,130 shares of the company’s stock, valued at approximately $25,000. Institutional investors own 0.39% of the company’s stock.

Evotec Company Profile

(Get Free Report)

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.

Further Reading

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with's FREE daily email newsletter.